An In Vitro–In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops
Open Access
- 2 September 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (9) , 1149
Abstract
Background/Objectives: The pulmonary administration of levodopa enables a rapid absorption and onset of action, making it a suitable administration route for managing OFF episodes in Parkinson’s disease. Currently, one dry powder product for inhalation (Inbrija) is available on the market, while another (Levodopa Cyclops) is in development. These two products differ substantially in terms of inhaler design, their use and resistance, and their powder formulations. This study aimed to investigate whether these differences translate into in vitro differences in aerosol characteristics and dissolution kinetics and whether any differences were also reflected in the in vivo performance. Methods: The in vitro aerosol characteristics were determined via Next Generation Impactor experiments, and the dissolution kinetics were determined with a modified paddle apparatus. A randomized crossover comparative bioavailability study with fasted healthy volunteers was conducted with Inbrija 84 mg and Levodopa Cyclops 45 mg, 90 mg, and 135 mg. Results: The results showed similar aerosol characteristics, but Levodopa Cyclops showed substantially faster dissolution behavior than Inbrija. Despite this in vitro difference, the pharmacokinetic profiles of Inbrija 84 mg and Levodopa Cyclops 90 mg were similar, with no differences in Cmax, Tmax, and AUC, showing bioequivalence between the two products. Conclusions: This suggests that the systemic absorption of levodopa via the lungs is not limited by dissolution but most likely by its permeation rate. This finding underscores the need to critically apply in vitro tests and critically interpret the results for predicting the in vivo performance of inhaled products.Keywords
This publication has 30 references indexed in Scilit:
- Central and peripheral lung deposition of fluticasone propionate dry powder inhaler formulations in humans characterized by population pharmacokineticsPharmaceutical Research, 2023
- Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's DiseaseClinical Therapeutics, 2020
- Searching for physiologically relevant in vitro dissolution techniques for orally inhaled drugsInternational Journal of Pharmaceutics, 2019
- A randomized trial of inhaled levodopa (CVT‐301) for motor fluctuations in Parkinson's diseaseMovement Disorders, 2016
- A levodopa dry powder inhaler for the treatment of Parkinson’s disease patients in off periodsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2015
- The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ familyEuropean Journal of Pharmaceutics and Biopharmaceutics, 2015
- Early DEtection of wEaring off in Parkinson disease: The DEEP studyParkinsonism & Related Disorders, 2014
- Characterisation of high dose aerosols from dry powder inhalersInternational Journal of Pharmaceutics, 2012
- Studies of the Rate Constant of l-DOPA Oxidation and Decarboxylation by HPLCChromatographia, 2012
- Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literatureMovement Disorders, 2001